

WHAT IS CLAIMED IS:

1. An affinity binding entity comprising an antigen binding domain comprising CDR sequences which are N-C ordered:

CDR1 Heavy Chain (HC)	SEQ ID NO: 309	SYGVH
CDR2 HC	SEQ ID NO: 310	VIWAGGTTNYSALMS
CDR3 HC	SEQ ID NO: 311	DGHFHFDF
CDR1 Light Chain (LC)	SEQ ID NO: 303	RASDIIYSNLA
CDR2 LC	SEQ ID NO: 304	AATNLAA
CDR3 LC	SEQ ID NO: 305	QHFWGSSIS

said affinity binding entity capable of binding HLA-A2/Tyr_{D369-377} in an MHC restricted manner.

2. An affinity binding entity comprising an antigen binding domain comprising CDR sequences which are N-C ordered:

CDR1 Heavy Chain (HC)	SEQ ID NO: 293	TSGMGVS
CDR2 HC	SEQ ID NO: 294	HIYWDDDKRYNPSLKS
CDR3 HC	SEQ ID NO: 295	KDYGSSFYAMHY
CDR1 Light Chain (LC)	SEQ ID NO: 287	KASQDIHNYIA
CDR2 LC	SEQ ID NO: 288	YTSTLQP
CDR3 LC	SEQ ID NO: 289	LQYDNLWT

said affinity binding entity capable of binding HLA-A2/Tyr_{D369-377} in an MHC restricted manner.

3. The affinity binding entity of any one of claims 1-2, being selected from the group consisting of an antibody, a CAR and a TCR.

4. The affinity binding entity of claim 3 comprising a therapeutic moiety.

5. The affinity binding entity of any one of claims 3-4, wherein said antibody is a single chain antibody, a bi-specific antibody or a full length antibody.

6. An expression vector comprising a polynucleotide comprising a nucleic acid sequence encoding the affinity binding entity of any one of claims 1-5 operably linked to a cis-acting regulatory element.

7. A cell comprising the expression vector of claim 6.

8. An *in vitro* method of detecting a cancer cell, comprising contacting the cell with the antibody of any one of claims 3-5, under conditions which allow immunocomplex formation, wherein a presence of said immunocomplex or level thereof is indicative of the cancer cell.

9. An *ex vivo* method of diagnosing cancer in a subject in need thereof, comprising contacting a cell of the subject with the antibody of any one of claims 3-5, under conditions which allow immunocomplex formation, wherein a presence of said immunocomplex or level thereof is indicative of the cancer.

10. Use of the affinity binding entity of any one of claims 1-5, the vector of claim 6 or the cell of claim 7 in the manufacture of a medicament for treating cancer.

11. The use of claim 10, wherein said cancer is selected from the group consisting of melanoma and glioblastoma.